Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Cardiology Testing January 8, 2026
HF Frailty Could Be Simpler than We Think January 8, 2026
A new registry analysis out of Japan suggests we may be able to simplify how we classify heart failure frailty without losing accuracy, allowing us to screen for HF mortality risk in faster and more practical ways. To see how CFS stacks up against comprehensive physical testing, researchers categorized 3.9k patients hospitalized with HF into […]
Cardiology Pharmaceuticals January 5, 2026
Aficamten Approved, Enter a New HCM Contender January 5, 2026
After years of dedicated research and careful science, Cytokinetics’ aficamten (Myqorzo) is officially FDA approved for obstructive hypertrophic cardiomyopathy, marking the company’s first-ever regulatory approval and ending BMS mavacamten’s reign as the only oHCM treatment. The FDA’s decision stemmed from the SEQUOIA-HCM trial, which demonstrated aficamten’s efficacy over 24 weeks in symptomatic obstructive HCM patients […]
Cardiology Business December 18, 2025
Philips Acquires SpectraWAVE, Making Azurion Even Better December 18, 2025
After taking a two and a half year break since its last acquisition, Philips acquired SpectraWAVE for its HyperVue and X1-FFR technologies in a bid to extend its intravascular imaging lead. At the center of this acquisition, Philips’ Azurion is an image-guided therapy platform that already serves 7.6M patients annually. It combines coronary imaging and […]
Cardiac Imaging December 15, 2025
CathWorks FFRangio Goes Beyond Physiology December 15, 2025
Despite society guidelines and extensive clinical evidence demonstrating that traditional wire-based coronary physiology improves outcomes and reduces costs compared to angiography alone1-2, physiology continues to be disappointingly underutilized globally due to the inconvenience and time it adds to the procedure. The novel CathWorks FFRangio System combines artificial intelligence and advanced computational science to obtain physiologic […]
More Stories
Surgeries & Interventions December 11, 2025
CAD and Treating it With PCI has No Impact on TAVR December 11, 2025
New post-hoc results from SCOPE I suggest that patients who have obstructive coronary artery disease as well as symptomatic severe aortic stenosis have similar outcomes to patients without CAD three years after TAVR. The study also suggests performing PCI in parallel to TAVR provides no benefit to these patients. But does the presence of CAD […]
Obesity Care December 8, 2025
Childhood Obesity CHD Risks Might Be Reversible December 8, 2025
Childhood obesity’s cardiovascular consequences might be reversible with timely intervention, after a Swedish study demonstrated that children who were overweight but achieved normal weight by young adulthood had similar coronary heart disease risk to their “never-overweight” peers. The BMI Epidemiology Study analysis linked health records to nationwide registries for 103k people in Sweden to track […]
Heart Failure December 4, 2025
How the Causes of Heart Failure Have Changed Over 35 Years December 4, 2025
A new NHANES analysis adds to the idea that heart failure might be more of a metabolic disease than just a cardiac problem, revealing that HF prevalence has remained constant over the last 35 years as ischemic causes decreased and metabolic factors increased. Examining over 30 years of data, the study analyzed 83.5k ambulatory participants […]
Cardiology Testing December 1, 2025
Risk Equations Fail Younger MI Patients December 1, 2025
Prevention guidelines might be failing younger patients, after a new JACC Advances analysis of first-MI patients under 65 revealed that over half would not have qualified for statins just two days before their cardiac event based on their ASCVD Risk Estimator Plus and PREVENT equations scores. Assessing these equations’ applicability to younger people, researchers examined […]
Cardiology Pharmaceuticals November 24, 2025
Winrevair Shows Early HFpEF Win in CADENCE November 24, 2025
Winrevair (sotatercept-csrk) might become Merck’s next blockbuster after positive Phase 2 results from the CADENCE study showed it led to significant improvements in pulmonary blood flow in patients with precapillary pulmonary hypertension due to HFpEF. Focused on exploring Winrevair’s HF impact, the Phase 2 CADENCE study enrolled 164 adults with PAH caused by HFpEF, comparing […]
Structural Heart November 20, 2025
Meril’s Myval Makes its Mark With LANDMARK November 20, 2025
The TAVR race might be closer to having another competitor in North America, after the LANDMARK trial’s one-year results suggest that Meril’s Myval THV series achieved comparable clinical efficacy to both Edwards’ Sapien and Medtronic’s Evolut AVR systems. The LANDMARK trial enrolled 768 patients with symptomatic severe aortic stenosis at 31 sites across 16 countries, […]
Atrial Fibrillation November 17, 2025
CLOSURE-AF Results Question Just How Good LAAO Is November 17, 2025
There’s been some serious debate over the last few years about whether or not left atrial appendage occlusion is actually the best stroke prevention option for high-risk AFib patients, and the latest results from the CLOSURE-AF trial suggest it might not be as effective as previously thought. To bring closure to the LAAO debate, CLOSURE-AF […]
Cardiology November 13, 2025
The Best of AHA 2025 November 13, 2025
Cardiology conference season is coming to a close, and what better way to end the year than with the AHA 2025 Scientific Sessions meeting in New Orleans, Louisiana. From major pharma studies to smaller companies solving big problems and every cardiac subspeciality in between, here are Cardiac Wire’s top takeaways from AHA 2025. AHA 2025 […]
Atrial Fibrillation November 10, 2025
ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025
Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]
Heart Failure November 6, 2025
PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025
Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]
Structural Heart November 3, 2025
Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025
New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]
Cardiology October 30, 2025
The Top Trends of TCT 2025 October 30, 2025
This year marked the 37th Annual Transcatheter Cardiovascular Therapeutics conference, and while the core of the conference is still catheter-based heart therapies, this year’s research studies and device demonstrations made it clearer than ever that cardiac medtech continues to push the boundaries of what can be done with a catheter. Structural Heart is King – […]
Cardiovascular Disease October 27, 2025
Genetic Risk Scores Improve CAD Detection October 27, 2025
Coronary artery disease risk assessment might soon rely on genetic testing, following a UK Biobank analysis that suggests adding a CAD multi-gene risk score to conventional biomarkers significantly improves disease prediction and patient identification. Examining genetic profiles, researchers followed 353k UK Biobank participants without baseline CAD for 11 years on average, and compared the predictive […]
Hypertension October 23, 2025
Intensive BP Lowering Doesn’t Hurt Patient QoL October 23, 2025
Intensive blood pressure lowering might enhance patient wellbeing, after the deeper analysis of the ESPRIT trial demonstrated that lowering systolic BP to <120 mmHg leads to modest but significant improvements in health-related quality of life. To fill in these gaps, the ESPRIT QoL analysis examined 5.4k intensive treatment and 5.4k standard treatment participants over a […]
Heart Failure October 20, 2025
Don’t Blame Your Heart for Heart Failure October 20, 2025
Perhaps the biggest cardiology story of the year, an entire issue of JACC now hypothesizes that heart failure with preserved ejection fraction (HFpEF) might actually be caused by visceral fat tissue that triggers cardiac weakening through adipokine signaling. The new unifying adiposity framework now proposes that visceral fat expansion causes secretion of an altered adipokine […]
Cardiology Business October 16, 2025
MedAxiom Report: Cardiologist Compensation Soars, Patient Access Struggles October 16, 2025
Good news and bad news from MedAxiom’s latest cardiology compensation survey. The good news? Cardiologist median compensation reached new record highs last year. The bad news? Patient access deteriorated while the number of patients physicians had to manage swelled. The 2025 survey findings aggregated data across cardiology, cardiac surgery, and vascular surgery specialties, examining compensation […]
Heart Failure October 13, 2025
Specialist Care Can Improve HF Outcomes Across the Board October 13, 2025
A recent study out of the U.K. suggests that multidisciplinary team management could significantly reduce death or rehospitalization risk for HF patients across the LVEF spectrum. Based in a single U.K. county, the Buckinghamshire analysis examined 2.1k patients hospitalized for acute heart failure who received either specialist care or standard care over a 618-day follow-up […]
Cardiology Testing October 9, 2025
Screening For Lp(a) is Still Too Uncommon October 9, 2025
A recent JACC analysis of the Epic Cosmos database suggests lipoprotein(a) screening is still one of cardiology’s most neglected risk assessment tools, representing a serious gap in the way we evaluate patients’ CVD risk. To learn more about Lp(a) testing trends, researchers searched for Lp(a) screening patterns in the Epic Cosmos database from 2015-2024 across […]